



EmphyCorp Phase III Clinical Trial with its Rx N115 Nonsteroidal Nasal Spray with no adverse effects for Moderate and Severe COPD Patients is planned for 2026

Flemington, NJ – July 15, 2025 - EmphyCorp Inc. www.EmphyCorp.com a private corporation, with several De-Risked late-stage drugs, specializes in Patented Rx Non-Steroidal Nasal and Oral Drug Sprays to treat Interstitial Lung Disease (orphan drug designation), Core Respiratory Diseases (COPD, Asthma), Allergic Rhinitis, Long COVID, Flu, COVID-19, Chronic Coughing, Hypertension, and OTC Products for the Cough/Cold Category. EmphyCorp has successfully completed (24) Phase II/III Clinical Trials with no adverse events reported.

Given the success of our Pivotal Randomized Double Blinded Placebo Controlled Phase III Clinical Trial in patients with Idiopathic Pulmonary Fibrosis (IPF) Coughing (73% reduction) and Improved Lung Function (Hypoxemia and Dyspnea), EmphyCorp announced a change to its Rx N115 Drug Pipeline to include a Randomized Double Blinded, Placebo Controlled Phase III Clinical Trial with its Rx N115 Nonsteroidal Nasal Spray for treating Moderate and Severe COPD Patients to begin in the 2nd Quarter 2026.

EmphyCorp has already completed (3) Randomized Double Blinded, Placebo Controlled Phase I/II Studies in Moderate and Severe COPD patients that produced clinically and statistically significant improvement in all lung functions including FEV-1, FVC, FEV-1/FVC Ratios and a decrease in Hypoxemia, Dyspnea, and a decrease in Oxygen Radicals. N115 Nasal Sprays have been shown to be safe and effective with no adverse effects reported.

True Innovation – Providing a better “Quality of Life” for Patients with COPD, Severe COPD, and Serious Respiratory Diseases without the use of albuterol, steroids, and anti-mucosal drugs and their side effects

Unlike other drug research approaches to combining multiple older Albuterol, Steroid, and Anti-Mucosal Drugs or combining bronchodilators in combination with anti-inflammatory drugs or agents that block inflammatory pathways (PDE3 and PDE4 inhibitors), for treating COPD and Severe COPD that have serious side effects, Patented Rx N115 Nonsteroidal Nasal Spray with no adverse effects utilizes a single Nasal Spray to increase the synthesis of Nasal Nitric Oxide to increase bronchodilation in COPD patients that also kills invading bacteria, fungi, and viruses to prevent infections, in addition to eliminating inflammatory cytokines (including the cytokine storm), and also eliminating oxygen radicals to produced clinically and statistically significant improvement in all lung functions including FEV-1, FVC, FEV-1/FVC Ratios thus eliminating Hypoxemia, Dyspnea and smokers cough.

Many of the symptoms we treated in successful Phase III Clinical Trials for Idiopathic Pulmonary Fibrosis (IPF), Pulmonary Fibrosis with COPD, Long COVID, and COVID-19 are the same symptoms we can treat in COPD Patients.

In a recently completed successful Pivotal Randomized Double Blinded Placebo Controlled Phase III Clinical Trial in patients with Idiopathic Pulmonary Fibrosis (IPF) Coughing (73% reduction) and Improved Lung Function (Hypoxemia and Dyspnea) with our Rx N115 Nonsteroidal Nasal Spray with no adverse events reported, produced a clinically and statistically significant decrease in coughing and improved lung function, while allowing all patients with Uncontrolled Coughing to sleep at night.

Rx N115 Nonsteroidal Nasal Spray produced clinically and statistically significant results in all sinus and lung functions including FEV-1, FVC, FEV-1/FVC Ratios with a decrease in Hypoxemia and Dyspnea. In a prior Phase II/III Clinical Trial for Pulmonary Fibrosis with COPD and IPF, also included a 52% to 86% improvement in Lung Function when removed from the use of a Steroid Spray.

Note: Diabetic and Hypertensives should not use Steroid Sprays because they are counter-indicated with the use of drugs taken for Diabetes and High Blood Pressure. Rx N115 Nonsteroidal Nasal Sprays have been shown to be safe in (24) Respiratory Clinical Studies to date including for the treatment of COPD and Severe COPD.

Dr. Alain Martin (CEO) created the EmphyCorp Patented Nasal and Oral Sprays, as well as Advanced Neosporin, Advanced Lubriderm, Early Pregnancy Test (EPT), Cool Mint Listerine, plus discovering the use of Rx Rezulin Drug for Type II Diabetes earlier in his career at Warner Lambert (Pfizer acquisition). He also created patented OTC and Rx products including next generation triple antibiotic, skincare, drug free post laser aftercare lotion with a cooling gel for pain, patented pet anxiety product (OTC or Rx) with no side effects for our sister company North Cell Pharmaceutical www.NorthCellPharma.com.

An Up-to-date Rx N115 Nasal Spray and Oral Spray Drug Pipeline, Peer Reviews, and Press Releases can be found on the EmphyCorp website www.EmphyCorp.com.

Please contact Robert Millar for more information and Partnership interest at 973-586-4421 or EmphyCorp@optonline.net.
